NasdaqGS:CLOV
NasdaqGS:CLOVHealthcare

Top Insider-Owned Growth Companies To Watch In January 2026

As the U.S. stock market experiences mixed movements with the Dow Jones and S&P 500 reaching fresh all-time highs, investors are keeping a close eye on geopolitical developments and economic indicators such as employment data. In this environment, growth companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those who know the business best and may offer resilience amid market fluctuations.
NasdaqGM:TKNO
NasdaqGM:TKNOLife Sciences

3 Promising Penny Stocks With Market Caps Up To $300M

Major stock indexes in the United States have recently shown mixed performance, with the Dow Jones Industrial Average and S&P 500 setting fresh all-time highs. Amid these fluctuating market conditions, investors are increasingly exploring diverse opportunities to maximize potential returns. Penny stocks, though a term from earlier market days, continue to represent intriguing investment prospects by offering access to smaller or newer companies at lower price points. By identifying those with...
NYSE:HIPO
NYSE:HIPOInsurance

Discovering Hidden Opportunities in US Stocks

As the Dow Jones and S&P 500 reach new all-time highs, the U.S. stock market continues to capture investors' attention amidst mixed economic signals, including a weakening labor market and geopolitical developments. In this dynamic environment, identifying promising small-cap stocks can offer valuable opportunities for growth, particularly when these companies demonstrate resilience and potential in sectors poised for expansion.
NasdaqGM:CRSP
NasdaqGM:CRSPBiotechs

Is CRISPR Therapeutics (CRSP) Attractively Priced After Recent Gene Editing Progress?

If you are trying to work out whether CRISPR Therapeutics is priced attractively right now, it helps to first line up what the recent share moves and current valuation are really telling you. The stock last closed at US$58.19, with returns of 9.4% over the past week, 2.3% over the past month, 8.2% year to date, 38.8% over the past year and 20.6% over three years, while the five year return sits at a 69.4% decline. Recent attention on CRISPR Therapeutics has been shaped by news around its...
NYSE:GD
NYSE:GDAerospace & Defense

Reassessing General Dynamics (GD) Valuation After Strong Multi Year Returns And Backlog Support

General Dynamics (GD) has drawn fresh attention as investors reassess major defense and aerospace names, with the stock recently closing at $360.71 after a year that included double digit total returns. See our latest analysis for General Dynamics. The recent move in General Dynamics' share price, including a 6.9% 1 month share price return and a 5.0% year to date share price return, sits alongside a 41.8% 1 year total shareholder return and 162.8% 5 year total shareholder return. This points...
NYSE:CHWY
NYSE:CHWYSpecialty Retail

Will Chewy’s (CHWY) Earnings Beat and Viking’s Stake Increase Shift Its Profit Narrative?

In its most recent quarter, Chewy reported US$3.12 billion in revenue, an 8.3% year-on-year increase that modestly exceeded analyst expectations and was accompanied by stronger-than-expected EBITDA performance. Shortly after these results, Viking Global Investors lifted its Chewy stake by very large double digits, highlighting strong institutional conviction in the company’s underlying business strength despite earlier pressure on the shares. Next, we’ll examine how Viking Global’s larger...
NYSE:SSB
NYSE:SSBBanks

Assessing SouthState Bank (SSB) Valuation After Recent Share Price Momentum And Long Term Returns

SouthState Bank (SSB) shares have been drawing attention after recent trading, with the stock last closing at $97.12. Investors are weighing this price against the bank’s earnings profile and overall return history. See our latest analysis for SouthState Bank. The recent 1-day share price return of 1.64% and 1-month share price return of 5.40% suggest some momentum is building, even though the 3.07% year to date share price return and 3.57% 1-year total shareholder return remain relatively...
NYSE:DOLE
NYSE:DOLEFood

Assessing Dole (DOLE) Valuation After Mixed Short Term Weakness And Stronger Multi Year Returns

Dole (NYSE:DOLE) has recently drawn attention after a mixed run in the stock, with a decline over the past month but a gain over the past 3 months. This has prompted closer scrutiny of its current valuation. See our latest analysis for Dole. Over the past year, Dole’s share price has had a softer year to date but a stronger 90 day run, while its 1 year and 3 year total shareholder returns point to more supportive longer term momentum. If Dole’s recent moves have you rethinking your watchlist,...
NasdaqGS:MEDP
NasdaqGS:MEDPLife Sciences

Is Medpace (MEDP) Using Its 52-Week High Consolidation to Redefine Its Clinical CRO Edge?

In recent months, Medpace Holdings has been consolidating near its 52-week high after a strong multi-month rally, while announcing that it will report its fourth quarter and fiscal year 2025 results on 9 February 2026, followed by a conference call on 10 February 2026. This period has highlighted continued optimism around Medpace’s leadership in complex outsourced clinical research and disciplined margin management, reinforced by generally constructive analyst views despite some valuation...
NasdaqCM:DCTH
NasdaqCM:DCTHMedical Equipment

A Look At Delcath Systems (DCTH) Valuation After New Phase 3 FOCUS Subgroup Data On HEPZATO KIT

Delcath Systems (DCTH) is back in focus after publishing detailed subgroup analyses from its phase 3 FOCUS study on HEPZATO KIT in unresectable metastatic uveal melanoma, helping refine how clinicians view efficacy and safety across different patient groups. See our latest analysis for Delcath Systems. The publication arrives after a mixed stretch for Delcath Systems, with a 30 day share price return of 6.85% and a 90 day share price return decline of 5.86%. The 3 year total shareholder...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Is It Too Late To Consider Halozyme Therapeutics (HALO) After A 43% One-Year Surge?

If you are asking whether Halozyme Therapeutics at around US$73.13 is still priced attractively, you are exactly who this breakdown is for. The stock has logged returns of 8.0% over the last week, 15.5% over the last month, and 42.9% over the past year, which naturally raises questions about growth potential and how much risk is now priced in. Recent coverage has focused on Halozyme Therapeutics as a US biotechnology company listed on the NASDAQ, with evergreen investor interest in how its...
NYSE:TWLO
NYSE:TWLOIT

A Look At Twilio (TWLO) Valuation After Piper Sandler Downgrade And Growth Concerns

Piper Sandler’s decision to cut Twilio (TWLO) to a Neutral rating after two years of a more positive stance, citing valuation and potential growth slowdown by 2026, has sharpened investor focus on the stock. See our latest analysis for Twilio. Recent trading reflects mixed momentum, with a 22.21% 3 month share price return and a 26.92% 1 year total shareholder return, even as the latest downgrade and debate around Twilio’s growth outlook have tempered some of the earlier enthusiasm. If...
NasdaqGM:FLY
NasdaqGM:FLYAerospace & Defense

Assessing Firefly Aerospace (FLY) Valuation After Class Action Lawsuits And Alpha Rocket Setback

Why Firefly Aerospace is Suddenly in the Spotlight Firefly Aerospace (FLY) has drawn intense attention after multiple law firms announced class action lawsuits alleging misleading disclosures around demand for its Spacecraft Solutions and the readiness of its Alpha rocket program. The complaints center on statements tied to Firefly's August 2025 IPO and subsequent disclosures, following disappointing financial results and an Alpha Flight 7 mission issue that coincided with sharp share price...
NasdaqGS:TENB
NasdaqGS:TENBSoftware

How Investors May Respond To Tenable Holdings (TENB) Expanding EMEA Reach Via Distology Exposure Management Partnership

Tenable Holdings recently announced a partnership with cybersecurity distributor Distology, adding its exposure management platform to Distology’s portfolio for channel partners across the UK, Europe, the Middle East, and Africa to help organizations assess and prioritize security risks across IT, cloud, and operational environments. This collaboration highlights how distributors are becoming central in getting unified exposure management tools into more regional markets, potentially...
NYSE:LUV
NYSE:LUVAirlines

Southwest Airlines (LUV) Valuation Check After 12.2% Monthly And 30.9% Three Month Share Price Moves

Southwest Airlines (LUV) shares have been getting attention after recent performance metrics showed a 12.2% move over the past month and a 30.9% gain in the past 3 months, prompting fresh interest in its valuation. See our latest analysis for Southwest Airlines. That recent 30.9% 3 month share price return comes on top of a 1 year total shareholder return of 32%. This suggests momentum has picked up again after a quieter year to date and refocuses attention on whether the current US$42.48...
NYSE:MTZ
NYSE:MTZConstruction

Is MasTec (MTZ) Still Reasonably Priced After Strong Multi‑Year Share Price Gains?

If you are wondering whether MasTec's recent share price puts it at a bargain or a stretch, you are in the right place to size up what that current price may mean for value. MasTec shares recently closed at US$236.35, with returns of 7.3% over the past week, 7.7% over the past month, 3.8% year to date and 61.4% over the past year, and 146.4% over three years and 193.5% over five years. These moves have kept MasTec on many investors' watchlists. They sit against a backdrop of ongoing interest...
NasdaqCM:NESR
NasdaqCM:NESREnergy Services

Why National Energy Services Reunited (NESR) Is Up 6.1% After Winning Multi‑Year Jafurah Fracturing Deal – And What's Next

National Energy Services Reunited Corp. recently presented at the Goldman Sachs Energy, CleanTech & Utilities Conference in Florida and has secured a multi-year unconventional fracturing contract in Saudi Arabia’s Jafurah field worth several billions over five years. This combination of greater investor visibility and a large, long-duration contract meaningfully extends the company’s revenue backlog and operational commitments in the MENA region. Next, we’ll examine how this multi-year...
NYSE:UBER
NYSE:UBERTransportation

Is It Time To Reassess Uber Technologies (UBER) After The Recent 30 Day Share Price Pullback

If you are wondering whether Uber Technologies stock still offers value at around US$85.54 per share, it helps to look closely at what the current price might already be assuming about its future. The share price has returned 4.2% over the last 7 days, after a 6.3% decline over the last 30 days, and it currently sits on a 29.3% return over 1 year and 205.1% over 3 years. Recent news has focused on Uber’s push to deepen its mobility and delivery footprint, as well as ongoing attention on ride...
NYSE:TTI
NYSE:TTIEnergy Services

Is TETRA’s Lithium and Low‑Carbon Investor Push Reframing the Core Story for TTI?

TETRA Technologies recently announced that its senior management participated in the 28th Annual Needham Growth Conference and the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference, hosting investor meetings and webcasts to outline its energy services, lithium, and low‑carbon technology initiatives. This heightened investor outreach, combined with growing attention on TETRA’s lithium and energy transition projects, has pushed the company into focus for higher‑risk,...
NYSE:ENR
NYSE:ENRHousehold Products

Assessing Energizer Holdings (ENR) Valuation After Recent Share Price Momentum Shift

Energizer Holdings (ENR) is back on investor radars after recent share price moves, with the stock showing mixed performance over the past year and longer term. This is prompting fresh questions about how its fundamentals line up. See our latest analysis for Energizer Holdings. The recent 1 day share price return of 5.32% and 1 month share price return of 10.87% come after a much weaker patch, with the 1 year total shareholder return at a 39.06% loss. This suggests short term momentum is...
NYSE:CFG
NYSE:CFGBanks

Citizens Financial Group (CFG) Valuation Check As Barclays Upgrade And EPS Growth Outlook Lift Sentiment

Citizens Financial Group (CFG) is back in focus after Barclays upgraded the stock, citing expectations around net interest margin trends, the buildout of its Private Bank, and ongoing transformation efforts. See our latest analysis for Citizens Financial Group. The Barclays upgrade lands on top of a strong run, with Citizens Financial Group’s share price at $62.14 and a 90 day share price return of 19.48%. The 1 year total shareholder return of 44.35% and 5 year total shareholder return of...
NYSE:PEG
NYSE:PEGIntegrated Utilities

A Look At Public Service Enterprise Group (PEG) Valuation After LIPA Extension And Leadership Changes

Public Service Enterprise Group (NYSE:PEG) is back in focus after New York State gave final approval to extend PSEG Long Island’s operations services agreement with LIPA through 2030, along with related leadership changes. See our latest analysis for Public Service Enterprise Group. The contract extension and leadership reshuffle come at a time when Public Service Enterprise Group’s 1 year total shareholder return is a 5.01% decline, while the 3 year and 5 year total shareholder returns of...
NYSE:ACVA
NYSE:ACVACommercial Services

Is ACV Auctions (ACVA) Pricing In Too Much Growth After A 57.9% One Year Decline

If you are wondering whether ACV Auctions at around US$8.55 is pricing in too much hope or not enough, you are in the right place to size up what the current market price might be implying. The stock has returned 5.0% over the last 7 days and 4.9% over the past month, although the 1 year return sits at a 57.9% decline, which may signal that expectations and perceived risk have shifted over time. Recent commentary around ACV Auctions has largely focused on its position in the online wholesale...
NasdaqGS:AGIO
NasdaqGS:AGIOBiotechs

Agios Pharmaceuticals (AGIO) Valuation Check After Recent RISE UP Data And Analyst Target Revisions

Agios Pharmaceuticals stock: recent performance context Agios Pharmaceuticals (AGIO) has seen mixed share performance recently, with a small move over the past week, a modest decline over the past month, and a sharper drop over the past 3 months. See our latest analysis for Agios Pharmaceuticals. At a share price of $27.47, Agios has a modest year to date share price return of 1.07%. However, the 90 day share price return of a 35.52% decline and the 1 year total shareholder return of a 21.78%...